Gary Meininger, M.D.
Gary Meininger, M.D. joined Vertex in 2019 as Senior Vice President, Global Medicines Development and Medical Affairs and Head of Pipeline Development. In this role, Dr. Meininger oversees the Translational Medicine function and the Clinical Development group for the General Medicine, Neurology and Pain disease areas, focused on advancing Vertex’s portfolio of investigational medicines.
Prior to Vertex, Dr. Meininger spent more than eight years at Janssen where he served as Vice President, Franchise Medical Leader in the Cardiovascular-Metabolism Therapeutic Area. In this strategic role, Dr. Meininger oversaw the design, development and conduct of study programs, as well as the associated regulatory interactions, filings and approvals for various products including INVOKANA® (canagliflozin) and INVOKAMET® (canagliflozin/metformin) for Type 2 Diabetes. Prior to joining Janssen, Dr. Meininger worked at Merck Research Laboratories for eight years where he was a core member of the JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) development programs and oversaw several development programs from Discovery through Late Development.
Dr. Meininger has been a member of the American Diabetes Association, American Society of Nephrology and American Association for the Study of Liver Diseases, as well as several European counterparts of these organizations, and has authored over 60 publications in metabolic, cardiovascular and renal disease. For the past 15 years, Dr. Meininger maintained an endocrine clinical practice at Robert Wood Johnson University Hospital where he taught medical students, residents and fellows, and he continues to retain a faculty appointment at Rutgers Medical School. He received a B.S. in Biological Sciences from Binghamton University and an M.D. degree from New York University School of Medicine. Dr. Meininger completed his residency in Internal Medicine at New York-Presbyterian Hospital and his fellowship in Endocrinology at the Massachusetts General Hospital.